PCVX vs. WST: Vaxcyte vs. West Pharmaceutical Services Stock Comparison

Company Profile

Vaxcyte (PCVX) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

West Pharmaceutical Services (WST) has more than two decades of public-market history since March 17, 1980, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

West Pharmaceutical Services (WST) at 18.81% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

West Pharmaceutical Services (WST) at 25.37% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: West Pharmaceutical Services (WST) reports revenue growth of 6.25%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Vaxcyte (PCVX) at 4.56 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Vaxcyte (PCVX) at 0.09 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Vaxcyte (PCVX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

A sales-based read is only available for West Pharmaceutical Services (WST), whose P/S ratio of 8.20 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.

Valuation Metrics